GAIASO Theranostics

📍 North Melbourne, Australia🗓 Founded 2025👥 6 employees💰 Last funded May 2025
Biotechnology Research
LinkedIn
GAIASO Theranostics exists to change outcomes in women’s cancers by developing more effective therapies, ultimately delivering longer, healthier and more dignified lives. We’re closing the gender gap in oncology by advancing a new generation of radiotheranostics. Built on the Affilin® protein-engineering platform and developed with our partners at PreMIT Pty Ltd, our programs combine precise tumour targeting, optimised biodistribution, and rational combinations to enhance efficacy. Our urgent mission is to accelerate life-saving options for more women, worldwide.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2025
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Germany
1
Frequently asked questions
Who invested in GAIASO Theranostics?
GAIASO Theranostics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did GAIASO Theranostics last raise funding?
The most recent investment in GAIASO Theranostics recorded on gritt.io was in May 2025.
When was GAIASO Theranostics founded?
GAIASO Theranostics was founded in 2025.
What industry is GAIASO Theranostics in?
GAIASO Theranostics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is GAIASO Theranostics based?
GAIASO Theranostics is headquartered in North Melbourne, Australia.